Article Text

other Versions

PDF
hMSH6: a potential diagnostic marker for oral carcinoma in situ
  1. Maryam Jessri1,
  2. Andrew J Dalley1,
  3. Camile S Farah1,2
  1. 1UQ Centre for Clinical Research, The University of Queensland, Brisbane, Queensland, Australia
  2. 2The Australian Centre for Oral Oncology Research & Education, Brisbane, Queensland, Australia
  1. Correspondence to Prof Camile S Farah, The Australian Centre for Oral Oncology Research & Education (ACORE), PO Box 88, Royal Brisbane & Women's Hospital, Herston, QLD 4029, Australia; camile{at}oralmedpath.com.au

Abstract

Oral medicine specialists rely upon accurate assessment of pathology to rationalise lesion management, especially for high-risk oral epithelial dysplasia, carcinoma in situ (CIS) and oral squamous cell carcinoma. Cross-discipline cancer research has highlighted the role of genetic instability in neoplasia. Improved diagnostic stringency from translation of immunostaining for DNA repair defects into current pathology practice has potential to benefit pathologists, clinicians and patients. The focus of this study was the obligatory and non-obligatory components of the MutLα and MutSα mismatch repair heterodimers, namely hMLH1, hMSH2, hPMS2 and hMSH6, which were studied in 274 formalin-fixed paraffin-embedded sections. A readily apparent inverse correlation between oral disease severity and both obligatory and non-obligatory components of MutLα and MutSα was observed (hMLH1, ρ=−0.715; hPMS2, ρ=−0.692; hMSH2, ρ=−0.728; and hMSH6, ρ=−0.702), with particularly conspicuous loss of hMSH6 expression from the stratum basale of CIS.

  • ORAL PATHOLOGY
  • IMMUNOHISTOCHEMISTRY
  • ONCOLOGY

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.